Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

Atara Biotherapeutics $ATRA is a leading off-the-shelf allogeneic TCellRx immunotherapy company developing products for patients Atara Biotherapeutics (NASDAQ: ATRA) is a biopharma company, developing fusion protein and T cell based immunotherapies for the treatment of cancer, kidney disease and cachexia.

Atara Biotherapeutics was formed in 2012, as a joint venture of Amgen and Kleiner Perkins Caufield & Byers (KPCB). Ataras lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”ATRA” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.atarabio.com
Founded2012
Disease Focus
Development Stage
STOCK CODENASDAQ: ATRA
Address
611 Gateway Blvd, Suite 900, CA 94080
San Francisco
United States
Email
Contact Number
+1 650-278-8930

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/atarabio” connections=”true” suffix=””]

Ataras off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Ataras T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Ataras most advanced T-cell immunotherapy in development, tab-cel_ (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab, as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

Pipeline

tab-cel_, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed rituximab, as well as other EBV-associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).

In Feb 2015, FDA granted tab-cel_ Breakthrough Therapy Designation for EBV+ PTLD following allogeneic hematopoietic cell transplant.

ATA520 is a cytotoxic T lymphocyte (CTL) product candidate that is precision targeted against the tumor associated antigen, wilms tumor 1 (WT1), and is being studied as a treatment for hematologic malignancies including multiple myeloma (MM) and plasma cell leukemia (PCL) in Phase 1 clinical trials.

Atara ATA274 is precision targeted against antigens expressed by the cytomegalovirus (CMV) using our selectively enhanced targeting technology. This product candidate is being studied for use as a treatment for Glioblastoma multiforme (GBM).

Atara Biotherapeutics is advancing six drugs licensed from Amgen Inc . through three companies: Pinta Biotherapeutics Inc. (PINTA 745), Santa Maria Biotherapeutics Inc. (STM 434, STM 217) and Nina Biotherapeutics Inc. (NINA 842).

In Sep. 2014, Atara Biotherapeutics entered into an exclusive option agreement with Memorial Sloan Kettering Cancer, under which it has the right to license the exclusive, worldwide rights to three clinical stage T-cell programs, including Epstein-Barr virus (EBV)-targeted cytotoxic T lymphocytes (CTLs), cytomegalovirus (CMV)-targeted CTLs, and Wilms Tumor 1 (WT1)-targeted CTLs.